Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results

Rhea-AI Summary

Neurocrine Biosciences (NBIX) has scheduled its first quarter 2025 financial results conference call and webcast for May 5, 2025, at 1:30 p.m. Pacific Time. The company will release its Q1 2025 financial results via press release at 1:00 p.m. PT on the same day.

Neurocrine Biosciences is a neuroscience-focused biopharmaceutical company with FDA-approved treatments for various conditions including tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids. The company maintains a pipeline of compounds in mid- to late-phase clinical development across its core therapeutic areas.

Conference Call and Webcast Scheduled for Monday, May 5

SAN DIEGO, April 14, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its first quarter 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on May 5, 2025.

The schedule for the press release and conference call / webcast is as follows:

• Q1 2025 Press Release: May 5, 2025 at 1:00 p.m. PT / 4:00 p.m. ET
• Q1 2025 Conference Call: May 5, 2025 at 1:30 p.m. PT / 4:30 p.m. ET
• Domestic Dial-In Number: 800-245-3047
• International Dial-In Number: 203-518-9765
• Conference ID: NBIX

The webcast can also be accessed on Neurocrine Biosciences' website under Investors at www.neurocrine.com. A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

About Neurocrine Biosciences

Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X and Facebook.
(*in collaboration with AbbVie)

NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.

View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-first-quarter-2025-financial-results-302427961.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences (NBIX) release its Q1 2025 earnings?

NBIX will release Q1 2025 earnings on May 5, 2025, at 1:00 p.m. Pacific Time (4:00 p.m. Eastern Time).

How can investors access NBIX's Q1 2025 earnings call?

Investors can access the call via phone (800-245-3047 domestic, 203-518-9765 international) or webcast through Neurocrine's website at www.neurocrine.com.

What therapeutic areas does NBIX currently have FDA-approved treatments for?

NBIX has FDA-approved treatments for tardive dyskinesia, Huntington's disease chorea, congenital adrenal hyperplasia, endometriosis, and uterine fibroids.

How long will NBIX's Q1 2025 earnings webcast be available for replay?

The webcast replay will be available on the company's website approximately one hour after the event and will be archived for approximately one month.